P365 Safety and Tolerability of Revefenacin, a Novel Once-Daily Nebulized Long-Acting Muscarinic Antagonist: Results of Two 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trials in Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease